Effect of garlic in improvement of metabolic syndrome

The effect of garlic powder supplementation on Metabolic Syndrome components, Fatty liver index, Intestinal function and Appetite Control in patients with metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180201038585N6

Enrollment

Registered

2020-02-22

Start date

2019-11-20

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METABOLIC SYNDROME. Endocrine, nutritional and metabolic diseases

Interventions

Intervention 1: Intervention group: The intervention group will be consume 4 tablets of 400 miligrams per day garlic. Intervention 2: Control group: The control group will be consume 4 tablets of 400

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 y Diagnosis of metabolic syndrome

Exclusion criteria

Exclusion criteria: Kidney disease Cardiovascular disease Type 1 and 2 diabetes Cancers Using blood pressure lower drugs Using blood sugar lower drugs Using anticoagulant drugs Psychiatric disorders Pregnancy and Lactation Allergy to garlic

Design outcomes

Primary

Measure	Time frame
HDL cholesterol. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.	—

Secondary

Measure	Time frame
Weight. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Scale, kg.;Body mass index. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.;Waist Circumference. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: BIA, cm.;Body fat percent. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: BIA.;Triglyceride. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;Systolic blood pressure. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Fatty liver index. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Formula.;Quantity of appetite. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: VAS questionnaire.;Intestinal function. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Bristol stool questionaire.;Fasting blood sugar. Timepoint: at the beginning of the	—

Measure

Time frame

Weight. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Scale, kg.;Body mass index. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.;Waist Circumference. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: BIA, cm.;Body fat percent. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: BIA.;Triglyceride. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Enzymatic method, mg/dl.;Systolic blood pressure. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Mercury sphygmomanometer, mmHg.;Fatty liver index. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Formula.;Quantity of appetite. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: VAS questionnaire.;Intestinal function. Timepoint: at the beginning of the study (before intervention), 6 and 12 weeks after intervention. Method of measurement: Bristol stool questionaire.;Fasting blood sugar. Timepoint: at the beginning of the

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactkarim Parastouei

Bagheiat-allah University of Medical Sciences

karimparastouei@gmail.com+98 21 8248 3264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026